Date:5/14/2009

future preclinical and clinical development may not have positive results; that we or our licensees may not be able to continue future development of our current and future development programs; that our development programs may never result in future product, license or royalty payments being received by BioCryst; that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates; that our actual burn rate may not be consistent with our expectations; that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (filed November 28, 2008), Quarterly Reports on Form 10-Q, and current reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in our projections and forward-looking statements.

BCRXW

'/>"/>

SOURCE BioCryst Pharmaceuticals Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine news :

1. BioCryst to Present at the 11th Annual BIO CEO & Investor Conference
2. BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009
3. BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
4. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
5. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
6. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
7. MAP Pharmaceuticals Announces Presentations at the American Thoracic Society International Conference
8. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
9. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
10. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
11. MAP Pharmaceuticals to Present at the Deutsche Bank Securities 34th Annual Health Care Conference